Knockdown of ZDHHC9 in the murine TNBC cell line 4T1 improved the tumor immune microenvironment, which may partly explain the cause of resistance to ICB therapy and provide a theoretical basis for combination therapy. Here, ZDHHC9 is linked to neoplasm.